CJC-1295 + Ipamorelin: The Clean GH Stack Explained

The Somatopause: Why GH Matters

Growth hormone (GH) is not just for growing taller. In adults, GH is essential for:

• Body composition: Promoting lean muscle mass and reducing visceral fat
• Sleep quality: Deep/delta sleep triggers the largest GH pulse of the day
• Skin and connective tissue: Collagen synthesis, wound healing, hair and nail quality
• Recovery: Tissue repair after exercise or injury
• Cognitive function: Neuroprotection and mood regulation

GH production peaks during puberty at roughly 1,500–2,000 mcg/day. By age 30, it begins declining at approximately 14% per decade — a process known as somatopause. By age 60, most adults produce 75–80% less GH than they did at age 25.

This decline drives the classic signs of middle-age deterioration: increased abdominal fat, decreased muscle mass, poor sleep, slow recovery, thinning skin, and reduced vitality.

GHRH vs GHRP: Two Sides of the GH Axis

The body regulates GH release through two complementary signalling systems:

GHRH (Growth Hormone Releasing Hormone)

• Produced in the hypothalamus
• Stimulates the pituitary to synthesise and release GH
• Think of it as pressing the "go" button on GH production

GHRP (Growth Hormone Releasing Peptide)

• Acts on ghrelin receptors (GHS-R) in the pituitary
• Amplifies the GH pulse triggered by GHRH
• Think of it as turning up the volume on the GH signal

Using both simultaneously produces a synergistic effect — the combined GH release is significantly greater than either alone. This is the fundamental principle behind the CJC-1295 + Ipamorelin stack.

CJC-1295: The GHRH Analogue

CJC-1295 is a synthetic analogue of GHRH (specifically, a modified version of GHRH amino acids 1-29). It stimulates the pituitary to produce and release GH through the same pathway as natural GHRH, but with significantly improved pharmacokinetics.

Key features:

• Extended half-life: The DAC (Drug Affinity Complex) version binds to albumin in the blood, extending the half-life from minutes to ~8 days. The no-DAC (modified GRF 1-29) version has a half-life of about 30 minutes — long enough for a therapeutic pulse but short enough to maintain pulsatility.
• Dose-dependent GH release: Higher doses produce proportionally larger GH pulses
• No desensitisation: The pituitary does not downregulate its response with repeated use
• Preserves natural rhythm: Unlike exogenous HGH, CJC-1295 works through the body's own regulatory mechanisms

At Mito Labs, we use the no-DAC version (modified GRF 1-29) because it preserves the natural pulsatile pattern of GH release — a critical distinction we will explore below.

Ipamorelin: The Selective GHRP

Ipamorelin is the most selective growth hormone releasing peptide ever developed. Its selectivity is what makes it uniquely suitable for long-term use.

Most GHRPs (like GHRP-2 or GHRP-6) stimulate GH release but also elevate:

• Cortisol (stress hormone — promotes fat storage, muscle breakdown, immune suppression)
• Prolactin (can cause mood changes, gynecomastia, libido reduction)
• Ghrelin/appetite (GHRP-6 is notorious for causing intense hunger)

Ipamorelin stimulates robust GH release while producing no significant increase in cortisol, prolactin, or appetite. This was demonstrated in multiple clinical studies, including Anderson et al. (2001) showing that even at supratherapeutic doses, Ipamorelin's cortisol and prolactin levels remained at baseline.

Key features:

• Selective GH release: Targets GHS-R1a specifically
• No cortisol spike: Safe for long-term use without adrenal stress
• No prolactin elevation: No risk of prolactin-related side effects
• Minimal appetite stimulation: Unlike GHRP-6
• Dose-dependent with a ceiling: GH release increases with dose up to a plateau — the body's own negative feedback prevents excessive GH

The Synergy: Why Combining Them Works

When CJC-1295 (GHRH pathway) and Ipamorelin (GHRP pathway) are administered together:

1. CJC-1295 tells the pituitary to "produce and release GH"
2. Ipamorelin simultaneously amplifies the release signal
3. The result is a GH pulse that is 2–3x larger than either peptide alone
4. This pulse mimics the amplitude and pattern of youthful GH secretion

Crucially, this is pulsatile release — the body gets a surge of GH followed by a return to baseline, just like natural physiology. This is fundamentally different from exogenous HGH.

Pulsatile vs Flat-Line: Why It Matters

Exogenous HGH (recombinant human growth hormone) provides a single large dose that creates sustained, non-pulsatile GH elevation. This flat-line pattern:

• Downregulates GH receptors (tolerance)
• Elevates IGF-1 to supraphysiological levels (potential cancer risk)
• Suppresses the body's own GH production
• Can cause side effects: joint pain, carpal tunnel, insulin resistance, water retention

CJC-1295 + Ipamorelin, by contrast:

• Maintains pulsatile rhythm (surge → baseline → surge)
• Preserves receptor sensitivity
• Does not suppress natural GH production
• Keeps IGF-1 within physiological range
• Minimal side effects (occasional injection site redness, mild water retention initially)

Feature	Exogenous HGH	CJC-1295 + Ipamorelin
GH pattern	Flat-line elevation	Natural pulsatile
Receptor downregulation	Yes, over time	No
Endogenous GH suppression	Yes	No
IGF-1 levels	Often supraphysiological	Physiological range
Side effect profile	Joint pain, insulin resistance, water retention	Mild, transient
Cost per month	$800–2,000+	Significantly less

Benefits

Patients on CJC-1295 + Ipamorelin consistently report:

• Deeper sleep within the first 1–2 weeks (often the first noticeable benefit)
• Fat loss — particularly visceral/abdominal fat — over 4–8 weeks
• Improved recovery from exercise and injury
• Lean muscle gain when combined with resistance training
• Better skin quality — improved thickness, hydration, and elasticity over 8–12 weeks
• Enhanced mood and mental clarity

Timing and Protocol

• Dose: CJC-1295 (no DAC) 100–300 mcg + Ipamorelin 100–300 mcg, combined in the same syringe
• Timing: Before bed, on an empty stomach (at least 2 hours after last meal). This synergises with the natural nocturnal GH pulse.
• Frequency: Daily, 5 days on / 2 days off, or daily for 4–8 week cycles
• Duration: 8–12 week cycles with 4-week breaks, or continuous use under clinical supervision

Important: GH release is blunted by food (especially carbohydrates and fats) and elevated blood sugar. Always inject on an empty stomach.

The Bottom Line

CJC-1295 + Ipamorelin is the gold standard peptide combination for restoring youthful GH secretion. It is cleaner than exogenous HGH, more selective than other GHRP combinations, and preserves the pulsatile rhythm that the body is designed to use. For anyone experiencing the effects of somatopause — declining sleep, increasing abdominal fat, slower recovery — this stack is the evidence-based starting point.

Mito Labs offers pharmaceutical-grade CJC-1295 (no DAC) and Ipamorelin, individually or as a convenient combination vial. All products include certificates of analysis for purity, sterility, and endotoxin testing.